Dr Qianxin Wu
Qianxin is interested in the functional of noncoding genome. She is fascinated by how hundreds and thousands of morphologically and functionally distinct cell types are being generated from the same genetic material. Qianxin is also passionate about developing novel biotechnology to answer the fundamental question of gene regulation. She joined Sanger human genome editing R&D team since 2017. Current, her research focuses on the following two areas: 1) Development of dead Cas9-based epigenetic modification systems (dCas9-EM) and use of thousands of uniquely inserted DNA barcodes to unbiasedly analyse context dependent dCas9-EM effects in human iPSCs and iNeurons. 2) Building a single cell sequencing screening platform to achieve large scale analysis of the functional non-coding genome using CRISPR. Her aim is to investigate the function of thousands of GWAS hits within one pooled screen. Prior to Sanger, Qianxin was a postdoc in Professor Tudor Fulga’s lab, Weatherall Institute, Oxford University. During her postdoc work, she has developed a genome engineering discovery platform, namely GenERA, enabling a systems-level functional characterisation of primary RNA regulatory networks. By generating and analysing thousands of CRISPR mutations, GenERA not only for the first time enables the unbiased dissection of gene regulatory landscape, but also provide the genetic based evidence that gene regulation within the untranslational region could be cooperative even the RNA cis-regulatory elements are in distal distance. Qianxin complete her Phd under supervision of Professor Nigel Gooderham at Imperial College London. During her PhD, she studied how a strong metabolic perturbation could change the entire metabolic network in a mouse model and whether gene expression controlled by microRNAs could explain these changes.